Literature DB >> 16184351

Expressing treatment-associated changes.

S Chrubasik1, C Conradt, A Black.   

Abstract

The Osteoarthritis Research Society International is attempting to establish a consensus on outcome measures, so as to facilitate comparability between different clinical studies in this area of research. There are no general recommendations on how changes in outcome measure (effect size) should be expressed. We therefore used data from a recently published study to express change as: a) the mean of the change from baseline divided by the individual baseline, b) the median of the change from baseline divided by the individual baseline, c) the mean of the change from baseline divided by the SD of baseline and d) the median of change from baseline divided by the SD of baseline. The results show that the correlations between different ways of expressing effect sizes were poor and the perceived relative magnitudes of various effects depended on how they were expressed. Organisations aiming at consensus ought to recommend the way in which change ought to be expressed. Until they do, authors should justify their choice of expression, particularly if it critically influences their conclusion, and/or present their data as fully as possible on a website.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16184351     DOI: 10.1007/s00393-005-0696-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  16 in total

1.  Comparison of a disease-specific and a generic instrument for measuring health-related quality of life in ankylosing spondylitis.

Authors:  Philip S Helliwell; Helena Marzo-Ortega; Alan Tennant
Journal:  Arthritis Rheum       Date:  2002-11

Review 2.  Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.

Authors:  Thao Pham; Désirée Van Der Heijde; Marissa Lassere; Roy D Altman; Jennifer J Anderson; Nicholas Bellamy; Marc Hochberg; Lee Simon; Vibeke Strand; Thasia Woodworth; Maxime Dougados
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

3.  [Antiarthritis effect of the Harpagophytum root; preliminary report].

Authors:  B ZORN
Journal:  Z Rheumaforsch       Date:  1958-04

4.  [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire].

Authors:  J Lautenschläger; W Mau; T Kohlmann; H H Raspe; F Struve; W Brückle; H Zeidler
Journal:  Z Rheumatol       Date:  1997 May-Jun       Impact factor: 1.372

5.  Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain: an open non-randomized study.

Authors:  S Chrubasik; O Künzel; A Black; C Conradt; F Kerschbaumer
Journal:  Phytomedicine       Date:  2001-07       Impact factor: 5.340

6.  Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip.

Authors:  S Chrubasik; J Thanner; O Künzel; C Conradt; A Black; S Pollak
Journal:  Phytomedicine       Date:  2002-04       Impact factor: 5.340

7.  OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

Authors:  T Pham; D van der Heijde; R D Altman; J J Anderson; N Bellamy; M Hochberg; L Simon; V Strand; T Woodworth; M Dougados
Journal:  Osteoarthritis Cartilage       Date:  2004-05       Impact factor: 6.576

Review 8.  The quality of clinical trials with Harpagophytum procumbens.

Authors:  S Chrubasik; C Conradt; A Black
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

9.  A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain.

Authors:  S Chrubasik; A Model; A Black; S Pollak
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

10.  Effectiveness of Harpagophytum procumbens in treatment of acute low back pain.

Authors:  S Chrubasik; C Zimpfer; U Schütt; R Ziegler
Journal:  Phytomedicine       Date:  1996-05       Impact factor: 5.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.